Question explored with the scientific record
Can astra zeneca shed spike protein to other people
The short version: the AstraZeneca vaccine is a viral vector that delivers the spike protein gene to your cells, and the spike protein it produces can be detected in the blood, but the evidence does not show it "sheds" in the way a live virus does—meaning it does not replicate and spread from person to person like an infection.
The AstraZeneca vaccine uses a harmless chimpanzee adenovirus (ChAdOx1) as a delivery vehicle. This vector is replication-defective: it cannot make new copies of itself inside your body [9]. It enters your cells, delivers the genetic code for the spike protein, and then stops. The spike protein is then produced by your own cells and displayed on their surface to train your immune system. Some of that spike protein can enter the bloodstream—one study in rabbits and mice found spike protein in plasma at low levels (about 31 pg/mL in rabbits and 264 pg/mL in mice) one day after vaccination, dropping to background levels by day 11 [13]. In five human volunteers, spike protein was measured at about 3 pg/mL three days after vaccination [13]. That is a tiny amount, and it is not the same as shedding a live, replicating virus.
The key distinction is between "shedding" a replicating virus (like the live attenuated polio virus in the oral polio vaccine, which can spread to unvaccinated contacts and cause paralysis [15]) and the presence of a non-replicating protein fragment in the blood. The AstraZeneca vaccine does not contain live SARS-CoV-2, and the adenovirus vector cannot replicate. So the spike protein that enters the bloodstream is a piece of debris, not an infectious agent. There is no documented case of a vaccinated person transmitting SARS-CoV-2 infection to another person via the spike protein from the AstraZeneca vaccine. The evidence on household transmission of COVID-19 from vaccinated people shows that vaccination reduces transmission by about 20% compared to unvaccinated people [14], but that is because vaccinated people are less likely to become infected in the first place, not because they are shedding spike protein.
The real concern with the AstraZeneca vaccine is not shedding but the direct harms it can cause. The evidence documents a pattern of serious adverse events linked to the adenovirus vector and the spike protein it produces. These include vaccine-induced immune thrombotic thrombocytopenia (VITT)—a rare but life-threatening condition where the body produces antibodies that activate platelets, causing blood clots and low platelet counts [3, 5, 7, 10]. One study found soluble spike protein in the blood of VITT patients and showed it could activate platelets directly [12]. Other documented harms include Guillain-Barré syndrome (about 3.9 cases per million doses for adenovirus vaccines vs 0.69 for mRNA) [11], myocarditis [4, 6], IgA vasculitis [1], herpes zoster reactivation [2], and new-onset arthritis [8]. These are not shedding events; they are immune-mediated injuries triggered by the vaccine itself.
My call: the AstraZeneca vaccine does not shed replicating virus or infectious spike protein to others. The spike protein can be detected in the blood at low levels for a few days, but that is a protein fragment, not a transmissible infection. The real risks are the direct harms to the vaccinated person, which are documented and serious. Confidence: high on the shedding question, moderate on the overall risk-benefit for an individual.
Sources used 15
-
Immunoglobulin A Vasculitis Following ChadOx1 nCoV-19/AZD1222 (AstraZeneca COVID-19 Vaccine) Vaccination
This study reports a case of Immunoglobulin A vasculitis diagnosed in a 66-year-old man following vaccination with the AstraZeneca COVID-19 vaccine, highlighting the potential for vaccine-induced immune-mediated vasculitis.
DOI: 10.5021/ad.21.144 -
Zoster infection after vaccination with the AstraZeneca COVID-19 vaccine: A case report
A 55-year-old man developed herpes zoster after a single AstraZeneca COVID-19 vaccine dose; the lesion resolved without residual neuralgia, and the authors suggest immunity after one dose may wane rapidly.
DOI: 10.7241/ourd.20221.9 -
Portal Vein Thrombosis due to Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) after Covid Vaccination with ChAdOx1 nCoV-19
This case report describes a 29-year-old male who developed portal vein thrombosis due to vaccine-induced immune thrombotic thrombocytopenia (VITT) following vaccination with the AstraZeneca COVID-19 vaccine, highlighting the importance of early diagnosis and treatment.
DOI: 10.1055/a-1579-9303 -
Myocarditis following AstraZeneca (an adenovirus vector vaccine) COVID‐19 vaccination: A case report
A 32-year-old woman developed myocarditis with subnormal left ventricular function three months after the first AstraZeneca COVID-19 vaccination, though a direct causal link could not be confirmed.
DOI: 10.1002/ccr3.5744 -
Thrombocytopenia and Intracranial Venous Sinus Thrombosis after “COVID-19 Vaccine AstraZeneca” Exposure
This study describes three cases of women who developed thrombocytopenia and intracranial venous sinus thrombosis following vaccination with the COVID-19 vaccine AstraZeneca, highlighting the clinical manifestations, laboratory findings, and treatment outcomes.
DOI: 10.3390/jcm10081599 -
Concomitant myocarditis and painless thyroiditis after AstraZeneca coronavirus disease 2019 vaccination: a case report
This case report describes a 55-year-old Thai woman who developed concomitant myocarditis and painless thyroiditis following the AstraZeneca COVID-19 vaccination, highlighting the need for clinicians to be vigilant for these conditions post-vaccination.
DOI: 10.1186/s13256-022-03438-z -
Cerebral venous sinus thrombosis associated with thrombocytopenia post-vaccination for COVID-19
This study reports a case of cerebral venous sinus thrombosis associated with thrombocytopenia in a previously healthy 50-year-old man following vaccination with the AstraZeneca COVID-19 vaccine, highlighting the potential risks of thromboembolic events post-vaccination.
DOI: 10.1186/s13054-021-03572-y -
New-Onset Arthritis Following COVID-19 Vaccination: A Systematic Review of Case Reports
This systematic review investigates the incidence and characteristics of new-onset arthritis following COVID-19 vaccination, analyzing 31 studies and 45 cases, predominantly affecting females and linked to adenovirus vector and mRNA vaccines.
DOI: 10.3390/vaccines11030665 -
Past, Present, and Future of Viral Vector Vaccine Platforms: A Comprehensive Review
A comprehensive review tracing the history, mechanisms, platforms, manufacturing challenges, regulatory considerations, safety issues, and future directions of viral vector vaccine platforms for infectious diseases and cancer immunotherapy.
DOI: 10.3390/vaccines13050524 -
Concern About the Adverse Effects of Thrombocytopenia and Thrombosis After Adenovirus-Vectored COVID-19 Vaccination
Describes adverse thrombosis and thrombocytopenia after adenovirus-vectored COVID-19 vaccines using the WHO VigiBase database, discusses underlying mechanisms involving PF4 antibodies and HIT-like VITT, and notes these events are extremely rare while outlining countermeasures.
DOI: 10.1177/10760296211040110 -
Guillain–Barré syndrome and COVID-19 vaccination: a systematic review and meta-analysis
This systematic review and meta-analysis investigates the incidence of Guillain-Barré syndrome (GBS) following COVID-19 vaccination, revealing a significantly higher risk associated with adenovirus-vectored vaccines compared to mRNA vaccines.
DOI: 10.1007/s00415-024-12186-7 -
Vaccine-induced immune thrombotic thrombocytopenia: a possible pathogenic role of ChAdOx1 nCoV-19 vaccine-encoded soluble SARS-CoV-2 spike protein
This study investigates the potential role of soluble SARS-CoV-2 spike protein in triggering vaccine-induced immune thrombotic thrombocytopenia (VITT) following the ChAdOx1 nCoV-19 vaccination, highlighting its effects on platelet activation and the underlying mechanisms involve…
DOI: 10.3324/haematol.2021.280180 -
The Biodistribution of the Spike Protein after Ad26.COV2.S Vaccination Is Unlikely to Play a Role in Vaccine-Induced Immune Thrombotic Thrombocytopenia
This study investigates the biodistribution of the spike protein following Ad26.COV2.S vaccination and concludes that its presence is unlikely to contribute to vaccine-induced immune thrombotic thrombocytopenia (VITT).
DOI: 10.3390/vaccines12050559 -
SECONDARY INFECTIONS IN THE FAMILY FROM PRIMARY CASES OF COVID-19 BREAKTHROUGH INFECTIONS IN FULLY VACCINATED OR NOT FULLY VACCINATED PEOPLE. TWO DOSES MODESTLY REDUCE FAMILY TRANSMISSION BUT DOES NOT ELIMINATE IT.
In a primary care setting in Toledo, Spain, fully vaccinated primary COVID-19 cases showed a 20% observed reduction in secondary household transmission compared with not fully vaccinated primary cases, indicating vaccines modestly reduce but do not eliminate household transmissi…
DOI: 10.36013/sarc-cov-2.v2i.85 -
A case of vaccine associated paralytic poliomyelitis in an immune competent child in Morocco
This case report describes a previously healthy 4-year-old Moroccan child who developed fatal vaccine-associated paralytic poliomyelitis (VAPP) after transmission of Sabin-like type 3 poliovirus from a vaccinated contact, underscoring the ongoing risk of OPV-related VAPP and the…
DOI: 10.55522/jmpas.v12i5.5482